Larimar therapeutics, inc.LRMR.US Overview

US StockHealthcare

(No presentation for LRMR)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

LRMR Overall Performance

LRMR AI Analysis & Strategy

LRMR Recent Performance

0.96%

Larimar therapeutics, inc.

0.81%

Avg of Sector

-1.14%

S&P500

LRMR PowerScanner

LRMR Key Information

LRMR Valuation Metrics

LRMR Earnings Table

LRMR Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.